| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Bancroft Robert E. | President & CEO, Director | C/O AEON BIOPHARMA, INC., 5 PARK PLAZA, SUITE 1750, IRVINE | /s/ Alexander Wilson, as attorney-in-fact for Robert E. Bancroft | 2025-05-16 | 0002066370 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AEON | Class A Common Stock | Award | $0 | +177K | $0.00 | 177K | May 14, 2025 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Class A Common Stock for each RSU upon vesting. 25% of the RSUs shall vest on each anniversary of April 29, 2025. |